Drug Utilization Review Board
Meeting Agenda
Thursday, August 14, 2025
7:15 a.m. to 8:30 a.m.
Google Meet joining info
Video call link: meet.google.com/zue-rrqz-rpb
Or dial: (US) +1 904-900-0180 PIN: 172 873 306#
Persons who wish to address the DUR Board may contact Luis Moreno at lmoreno@utah.gov prior to the meeting or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.
1) Call to order - Sharon Weinstein, MD
a) Welcome and Introductions
b) Review and Approval of Minutes
2) Prior Authorization Updates - Luis Moreno, PharmD
a) Spravato (esketamine)
3) Review Topic
a) Journavx (suzetrigine) DRRC Report - Monet Luloh, PharmD
i) Utilization Review - Luis Moreno, PharmD
ii) Committee Discussion/Questions
4) Public Comment
5) Review Prior Authorization Criteria
a) Kebilidi (eladocagene exuparvovec-tneq) - Kyu Yun Park, PharmD
i) Committee Discussion/Questions
ii) Committee Action
b) Yeztugo (lenacapavir) - Iris Wan, PharmD
i) Committee Discussion/Questions
ii) Committee Action
c) Skysona (elivaldogene autotemcel) - Luis Moreno, PharmD
i) Committee Discussion/Questions
ii) Committee Action
d) Piqray (alpelisib) - Luis Moreno, PharmD
i) Committee Discussion/Questions
ii) Committee Action
6) Next Meeting
a) September 11, 2025 - Oral buprenorphine plus full opioid agonist outside of opioid use disorder review, and new prior authorization criteria for Adzynma and Cablivi.
7) Adjourned - Sharon Weinstein, MD
Notice of Special Accommodations (ADA)
In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Luis Moreno at 801-538-6155.
Notice of Electronic or Telephone Participation
Video call link: meet.google.com/zue-rrqz-rpb
Or dial: (US) +1 904-900-0180 PIN: 172 873 306#